Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Hochhauser

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
JAMA Oncology|December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 StudyManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Cancer Research|September 18, 2004
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activityJohn A Hartley, Victoria J Spanswick, Natalie Brooks, et al.
Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Gut|December 14, 2017
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancerMark Lawler, Deborah Alsina, Richard A Adams, et al.
The New England Journal of Medicine|June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric CancerKohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.
Nature Genetics|July 2, 2024
Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancerHamzeh Kayhanian, William Cross, Suzanne E M van der Horst, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
JAMA Oncology|December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 StudyManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Cancer Research|September 18, 2004
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activityJohn A Hartley, Victoria J Spanswick, Natalie Brooks, et al.
Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Gut|December 14, 2017
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancerMark Lawler, Deborah Alsina, Richard A Adams, et al.
The New England Journal of Medicine|June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric CancerKohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.
Nature Genetics|July 2, 2024
Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancerHamzeh Kayhanian, William Cross, Suzanne E M van der Horst, et al.
Pageof 7